Meeting NewsVideo

VIDEO: Biologics show efficacy, safety in patients with giant cell arteritis

DESTIN, Fla. — At the Congress of Clinical Rheumatology Annual Meeting, Robert F. Spiera, MD, from Hospital for Special Surgery, spoke about the need to find a steroid-sparing agent for patients with giant cell arteritis (GCA) and how biologics have shown efficacy and safety in some small studies for these patients.

Spiera mentioned abatacept, which demonstrated efficacy in a placebo-controlled trial of 50 patients, and tocilizumab, which showed a steroid-sparing benefit and maintenance of relapse-free survival in another published study.

DESTIN, Fla. — At the Congress of Clinical Rheumatology Annual Meeting, Robert F. Spiera, MD, from Hospital for Special Surgery, spoke about the need to find a steroid-sparing agent for patients with giant cell arteritis (GCA) and how biologics have shown efficacy and safety in some small studies for these patients.

Spiera mentioned abatacept, which demonstrated efficacy in a placebo-controlled trial of 50 patients, and tocilizumab, which showed a steroid-sparing benefit and maintenance of relapse-free survival in another published study.

    See more from Congress of Clinical Rheumatology Annual Meeting